Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease

NCT03109080 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT03109080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03109080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Lead sponsor
Institut Curie
Phase
Phase 1
Overall status
Completed
Start date
July 24, 2017
Completion date
November 29, 2021
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm malignant female, breast neoplasms, triple-negative, radiotherapy side effect